Rheumatoid Arthritic Pain – Epidemiology – Europe
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan) and other European countries. We report the prevalence of RA pain for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s RA pain forecast will answer the following questions:
- Of all people diagnosed with RA pain, how many in each country in the developed world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of RA pain over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts two RA pain patient populations, as follows:
- Diagnosed prevalent cases of RA joint pain.
- Diagnosed drug-treated prevalent cases of RA joint pain.
Note: coverage may vary by country.
Table of contents
- Rheumatoid Arthritic Pain - Epidemiology - Europe
- Epidemiology data
- Methods
- Literature review (studies included in / excluded from the analyses of rheumatoid arthritis pain)
- Diagnosed prevalent cases
- Diagnosed drug-treated prevalent cases
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviations
Navya Vardhan, M.Sc., Epidemiologist, Epidemiology. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.
Stephanie Niquita Phankon, M.B.B.S., M.P.H., Manager, Epidemiology. Ms. Phankon’s expertise is in autoimmune and inflammatory diseases and hematological malignancies. She holds a master’s in public health specializing in epidemiology from TISS in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China. She has been trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects.